P2Y Receptor Agonist

P2Y Receptor Agonists (35):

Cat. No.	Product Name	Effect	Purity

HY-N7032

Uridine 5′-diphosphoglucose disodium salt	Agonist	99.83%
Uridine 5’-diphosphoglucose (UDP-glucose) disodium salt, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium salt is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium salt is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.

HY-113044R

Uridine diphosphate glucose (Standard)	Agonist
Uridine diphosphate glucose (Standard) is the analytical standard of Uridine diphosphate glucose. This product is intended for research and analytical applications. Uridine diphosphate glucose is the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine diphosphate glucose is an agonist of the P2Y₁₄ receptor, a neuroimmune system GPCR.

HY-108651

Uridine-5'-O-(3-thiotriphosphate) trisodium	Agonist
Uridine-5'-O-(3-thiotriphosphate) trisodium, a stable analogue of UTP, is a potent agonist of the P2Y2 and P2Y4 receptors with increased metabolic stability.

HY-114364

UDP-Galactose disodium	Agonist	99.42%
UDP-Galactose disodium is a natural agonist of the P2Y₁₄ receptor with an EC₅₀ of 0.67 μM for the hP2Y₁₄ receptor. UDP-Galactose disodium is a substrate for the transferase beta-1, 4 galactosyltransferase V (B4GALT5). In addition, UDP-Galactose disodium is required for the biosynthesis of several abundant glycoconjugates that form the surface glycocalyx of Leishmania major.

HY-B0606

Diquafosol tetrasodium	Agonist	≥99.0%
Diquafosol tetrasodium is a P2Y2 receptor agonist that stimulates fluid and mucin secretion on the ocular surface, as a topical treatment of dry eye disease.

HY-108661A

NF546 hydrate	Agonist
NF546 (hydrate) is a selective non-nucleotide P2Y11 agonist with a pEC₅₀ of 6.27. NF546 (hydrate) stimulates release of interleukin-8 from human monocyte-derived dendritic cells.

HY-108648

2-MeS-ADP trisodium	Agonist	98.70%
2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC₅₀s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC₅₀s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1.

HY-154840

4-Thiouridine 5′-triphosphate tetralithium	Agonist
4-Thiouridine 5′-triphosphate (4-Thio-UTP) tetralithium is a potent P2Y₂ and P2Y₄ receptor agonist, with EC₅₀s of 35 and 350 nM for hP2Y₂ and hP2Y₄, respectively. 4-Thiouridine 5′-triphosphate tetralithium can be used in the study of crosslinking experiments, labeling of transcriptional complex.

HY-113359AS2

Uridine 5'-diphosphate-¹³C₉,¹⁵N₂ dilithium	Agonist	99.5%
Uridine 5'-diphosphate-¹³C₉,¹⁵N₂ dilithium is ¹³C and ¹⁵N-labeled Uridine 5'-diphosphate (HY-113359). Uridine 5'-diphosphate is a P2Y₆ receptor agonist with an EC₅₀ of 0.013 μM for human P2Y₆ receptor.

HY-108656

MRS2365	Agonist
MRS2365 is a potent and selective P2Y1 receptor (EC₅₀=0.4 nM) /[³⁵S]GTPγS binding/β-arrestin 2 recruitment agonist with an EC₅₀ of 0.4 nM. MRS2365 relieves mechanical allodynia and increases mechanical sensitivity. MRS2365 shows little agonist or antagonist activity at the P2Y12 or P2Y13 receptors.

HY-108656A

MRS2365 trisodium	Agonist	≥99.0%
MRS2365 trisodium is a potent and selective P2Y1 receptor (EC₅₀=0.4 nM)/[³⁵S]GTPγS binding/β-arrestin 2 recruitment agonist. MRS2365 trisodium relieves mechanical allodynia and increases mechanical sensitivity.

HY-108649A

MRS2768 tetrasodium salt	Agonist	98.70%
MRS2768 tetrasodium salt is a moderately potent and selective P2Y2 receptor agonist. MRS2768 tetrasodium salt has a protective effect on cardiomyocytes from ischemic damage in vivo and in vitro.

HY-113044

Uridine diphosphate glucose	Agonist
Uridine diphosphate glucose is the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine diphosphate glucose is an agonist of the P2Y₁₄ receptor, a neuroimmune system GPCR^1.

HY-108661

NF546	Agonist
NF546 is a selective non-nucleotide P2Y11 agonist with a pEC₅₀ of 6.27. NF546 stimulates release of interleukin-8 from human monocyte-derived dendritic cells.

HY-134361

ATP-γ-S tetrasodium	Agonist
ATP-γ-S tetrasodium, an ATP analogue, is a P2Y11 receptor agonist. ATP-γ-S tetrasodium is active in ATP hydrolysis. ATP-γ-S tetrasodium is also an antioxidant and neuroprotectant.

HY-108664

MRS2957	Agonist
MRS2957 is a P2Y6 receptor agonist that activates AMPK in pancreatic β-cells, promoting insulin secretion and reducing apoptosis, thereby holding potential as a therapeutic target for type 2 diabetes.

HY-150524

UDP-Galactose	Agonist
UDP-Galactose is a monosaccharide involved in nucleotide sugar metabolism. UDP-Galactose and its derivatives act as a natural agonist for G_i protein-conjugated P2Y₁₄ receptors in the immune system (IC₅₀=0.67 μM, hP2Y₁₄).

HY-113359AS1

Uridine 5'-diphosphate-¹³C₉ dilithium	Agonist
Uridine 5'-diphosphate-¹³C₉ dilithium is ¹³C-labeled Uridine 5'-diphosphate (HY-113359). Uridine 5'-diphosphate is a P2Y₆ receptor agonist with an EC₅₀ of 0.013 μM for human P2Y₆ receptor.

HY-113359

Uridine 5'-diphosphate	Agonist
Uridine 5'-diphosphate is a P2Y₆ receptor agonist with an EC₅₀ of 0.013 μM for human P2Y₆ receptor.

HY-108648A

2-MeSADP	Agonist
2-MeSADP (2-Methylthioadenosine diphosphate; 2-Methylthio-ADP) is a potent purinergic P2Y receptors agonist, with EC₅₀s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-MeSADP has pEC₅₀s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-MeSADP induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1.

Name
Email *

	Sorry, but the email address you supplied was invalid.